Chemistry Wealth Management Raises UnitedHealth Group Stake 59.2% to 16,199 Shares Valued at $5.59M
Chemistry Wealth Management LLC raised its UNH stake by 59.2% to 16,199 shares valued at $5.59 million in Q3, making it the fund’s 18th largest holding. Institutional investors Norges Bank and Berkshire Hathaway added multibillion-dollar UNH stakes in Q2, while RBC and UBS analysts lifted price targets to $408 and $430.
1. Chemistry Wealth Management Significantly Increases UNH Exposure
In its latest SEC filing, Chemistry Wealth Management LLC reported a 59.2% increase in its UnitedHealth Group stake during the third quarter, acquiring an additional 6,022 shares to bring its total holding to 16,199 shares. This position now represents approximately 1.1% of the firm’s overall portfolio and ranks as its 18th largest holding. At the end of the reporting period, the value of this stake stood at $5.59 million, underscoring the fund’s conviction in UnitedHealth Group’s long-term growth prospects within the healthcare services sector.
2. Major Institutions Continue to Build Positions
Several blue-chip asset managers have also bolstered their exposure to UnitedHealth Group. Norges Bank initiated a new position valued at approximately $3.84 billion in the second quarter, while Berkshire Hathaway launched its own stake worth roughly $1.57 billion over the same period. Dodge & Cox more than doubled its investment, adding 4.73 million shares to reach a total holding valued at about $2.73 billion. Similarly, Lone Pine Capital and Amundi expanded their positions by establishing new stakes of $528 million and increasing existing holdings by 33.8% to $1.90 billion, respectively. Institutional investors now control nearly 88% of UnitedHealth Group’s outstanding shares.
3. Recent Earnings and Financial Metrics Highlight Resilience
In its most recent quarterly report, UnitedHealth Group delivered earnings per share of $2.92, surpassing consensus estimates by $0.05, and generated revenue of $113.16 billion, marking a 12.2% year-over-year increase. The company reported a net margin of 4.04% and a return on equity of 19.23%, reflecting disciplined cost management across its UnitedHealthcare and Optum business platforms. Analysts project full-year EPS of 29.54, supported by strong membership growth in commercial and government-sponsored health plans and continued expansion of high-margin care delivery and pharmacy services.
4. Analyst Community Maintains Positive Outlook
The majority of Wall Street research firms remain constructive on UnitedHealth Group’s outlook. Seventeen analysts assign a Buy rating, nine maintain a Hold recommendation, and three express Sell views, resulting in a consensus stance of Hold. Recent commentary highlights the company’s diversified revenue streams and margin expansion potential as catalysts for further multiple expansion. Upgrades from leading brokerages have emphasized favorable demographic trends, accelerating adoption of value-based care and solid recurring revenue from managed care contracts.